menu
    • menu

    Company profile for Ubiquigent

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ubiquigent Limited enables & supports protein degradation focused drug discovery via modulation and exploitation of the ubiquitin system. Our chemistry and biology platforms allow us to design & develop novel compounds as part of strategic partnerships. In parallel we also provide access to our platforms and capabilities for the evaluation of our partners’ compounds. Ubiquigent provides support to programmes at all stages fr...
    Ubiquigent Limited enables & supports protein degradation focused drug discovery via modulation and exploitation of the ubiquitin system. Our chemistry and biology platforms allow us to design & develop novel compounds as part of strategic partnerships. In parallel we also provide access to our platforms and capabilities for the evaluation of our partners’ compounds. Ubiquigent provides support to programmes at all stages from the provision of assay development and compound profiling Drug Discovery Screening Platform and Research Tools, through to larger Collaborative Drug Discovery partnerships for the delivery of hit & lead compounds.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ubiquigentunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Sir James Black Centre Dow Street Dundee DD1 5EH Scotland
    Telephone
    Telephone
    +44 (0) 1382 381147
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ubiquigent.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ubiquigent
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ubiquigent

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alleo And Ubiquigent Enter AI-Driven Drug Discovery Partnership
    Alleo And Ubiquigent Enter AI-Driven Drug Discovery Partnership

    15 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241015512051/en

    BUSINESSWIRE
    15 Oct 2024
    Share Share
    Ubiquigent and Debiopharm team up to advance USP1 inhibitor
    Ubiquigent and Debiopharm team up to advance USP1 inhibitor

    27 Mar 2024

    // Jenna Philpott PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/ubiquigent-and-debiopharm-team-up-to-advance-usp1-inhibitor/

    Jenna Philpott PHARMACEUTICAL TECHNOLOGY
    27 Mar 2024
    Share Share
    Ubiquigent and Debiopharm Enter Agreement to Support for Debio 0432
    Ubiquigent and Debiopharm Enter Agreement to Support for Debio 0432

    26 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240326540510/en

    BUSINESSWIRE
    26 Mar 2024
    Share Share
    Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
    Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics

    11 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240311216568/en

    BUSINESSWIRE
    11 Mar 2024
    Share Share
    Ubiquigent DUB inhibitor pact survives Bristol-Celgene merger
    Ubiquigent DUB inhibitor pact survives Bristol-Celgene merger

    19 Jun 2020

    //  Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ubiquigent-dub-inhibitor-pact-survives-bristol-celgene-merger

     Nick Paul Taylor FIERCE BIOTECH
    19 Jun 2020
    Share Share
    Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb
    Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb

    17 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200617005035/en

    BUSINESSWIRE
    17 Jun 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search